全文获取类型
收费全文 | 824篇 |
免费 | 86篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 33篇 |
妇产科学 | 12篇 |
基础医学 | 122篇 |
口腔科学 | 1篇 |
临床医学 | 52篇 |
内科学 | 94篇 |
皮肤病学 | 27篇 |
神经病学 | 126篇 |
特种医学 | 41篇 |
外科学 | 62篇 |
综合类 | 19篇 |
一般理论 | 5篇 |
预防医学 | 213篇 |
眼科学 | 7篇 |
药学 | 45篇 |
中国医学 | 1篇 |
肿瘤学 | 34篇 |
出版年
2022年 | 10篇 |
2021年 | 8篇 |
2020年 | 6篇 |
2019年 | 10篇 |
2018年 | 19篇 |
2017年 | 15篇 |
2016年 | 12篇 |
2015年 | 28篇 |
2014年 | 22篇 |
2013年 | 46篇 |
2012年 | 37篇 |
2011年 | 54篇 |
2010年 | 23篇 |
2009年 | 22篇 |
2008年 | 45篇 |
2007年 | 47篇 |
2006年 | 33篇 |
2005年 | 29篇 |
2004年 | 28篇 |
2003年 | 20篇 |
2002年 | 24篇 |
2001年 | 12篇 |
2000年 | 15篇 |
1999年 | 12篇 |
1998年 | 15篇 |
1997年 | 11篇 |
1996年 | 9篇 |
1995年 | 11篇 |
1994年 | 6篇 |
1992年 | 12篇 |
1991年 | 15篇 |
1990年 | 21篇 |
1989年 | 10篇 |
1988年 | 16篇 |
1987年 | 16篇 |
1986年 | 21篇 |
1985年 | 21篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 5篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1979年 | 14篇 |
1978年 | 7篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1971年 | 5篇 |
1970年 | 8篇 |
1969年 | 7篇 |
1962年 | 4篇 |
排序方式: 共有911条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
Karen W. Gripp Lindsey A. Morse Marni Axelrad Kathryn C. Chatfield Aaron Chidekel William Dobyns Daniel Doyle Bronwyn Kerr Angela E. Lin David D. Schwartz Barbara J. Sibbles Dawn Siegel Suma P. Shankar David A. Stevenson Mihir M. Thacker K. Nicole Weaver Sue M. White Katherine A. Rauen 《American journal of medical genetics. Part A》2019,179(9):1725-1744
Costello syndrome (CS) is a RASopathy caused by activating germline mutations in HRAS. Due to ubiquitous HRAS gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. Individuals with CS may have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues; however, considerable overlap with other RASopathies exists. Medical evaluation requires an understanding of the multifaceted phenotype. Subspecialists may have limited experience in caring for these individuals because of the rarity of CS. Furthermore, the phenotypic presentation may vary with the underlying genotype. These guidelines were developed by an interdisciplinary team of experts in order to encourage timely health care practices and provide medical management guidelines for the primary and specialty care provider, as well as for the families and affected individuals across their lifespan. These guidelines are based on expert opinion and do not represent evidence‐based guidelines due to the lack of data for this rare condition. 相似文献
9.
10.
Protriptyline in obstructive sleep apnea: a double-blind trial 总被引:6,自引:0,他引:6
L G Brownell P West P Sweatman J C Acres M H Kryger 《The New England journal of medicine》1982,307(17):1037-1042
We evaluated protriptyline, a nonsedating tricyclic antidepressant, as a treatment for obstructive sleep apnea in a double-blind crossover study of five men. After two weeks of treatment, with no change in body weight, daytime somnolence was markedly reduced and nocturnal oxygenation was improved, although apnea duration and frequency were not significantly decreased. Rapid-eye-movement (REM) stage time as a fraction of the total sleep time was reduced during treatment from 0.231 +/- 0.031 to 0.107 +/- 0.013 (mean +/- S.E.M.) (P less than 0.05). REM apnea time as a fraction of total sleep time was reduced from 0.145 +/- 0.022 to 0.054 +/- 0.006 (P less than 0.05). REM reduction during treatment with protriptyline can account for decreased REM apnea time. Similar decreases in REM stage time and REM apnea duration and similar improvement in oxygenation continued after six months of treatment. In addition, body weight, apnea, and arousal frequency were decreased at this time. Although the obstructive sleep apnea was not resolved, it was reduced. Protriptyline can be effective in patients with sleep apnea when the disorder is not life-threatening. 相似文献